Renaissance Technologies LLC Boosts Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)

Renaissance Technologies LLC grew its holdings in Mineralys Therapeutics, Inc. (NASDAQ:MLYS) by 95.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 61,800 shares of the company’s stock after acquiring an additional 30,100 shares during the period. Renaissance Technologies LLC owned about 0.12% of Mineralys Therapeutics worth $723,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. PNC Financial Services Group Inc. boosted its holdings in Mineralys Therapeutics by 17,821.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 4,122 shares of the company’s stock valued at $35,000 after purchasing an additional 4,099 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Mineralys Therapeutics by 67.0% during the first quarter. China Universal Asset Management Co. Ltd. now owns 7,931 shares of the company’s stock worth $102,000 after acquiring an additional 3,181 shares during the period. Bellevue Group AG purchased a new position in Mineralys Therapeutics during the first quarter valued at approximately $119,000. Federated Hermes Inc. lifted its holdings in Mineralys Therapeutics by 100.0% in the second quarter. Federated Hermes Inc. now owns 12,000 shares of the company’s stock valued at $140,000 after acquiring an additional 6,000 shares during the period. Finally, Rhumbline Advisers boosted its position in Mineralys Therapeutics by 82.1% in the 2nd quarter. Rhumbline Advisers now owns 41,079 shares of the company’s stock worth $481,000 after purchasing an additional 18,519 shares in the last quarter. Institutional investors and hedge funds own 84.46% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Mineralys Therapeutics in a report on Thursday, August 15th.

Mineralys Therapeutics Stock Down 0.4 %

Shares of Mineralys Therapeutics stock opened at $13.60 on Wednesday. The firm has a market cap of $675.23 million, a PE ratio of -6.21 and a beta of 1.93. Mineralys Therapeutics, Inc. has a twelve month low of $5.85 and a twelve month high of $16.91. The business has a 50-day moving average price of $11.74 and a 200 day moving average price of $12.39.

Mineralys Therapeutics (NASDAQ:MLYS) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.10). During the same quarter last year, the firm posted ($0.31) earnings per share. On average, sell-side analysts expect that Mineralys Therapeutics, Inc. will post -3.08 EPS for the current year.

Insiders Place Their Bets

In other news, Director Brian Taylor Slingsby sold 550,000 shares of the business’s stock in a transaction dated Wednesday, July 24th. The shares were sold at an average price of $13.05, for a total transaction of $7,177,500.00. Following the completion of the sale, the director now owns 8,644,579 shares of the company’s stock, valued at $112,811,755.95. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Mineralys Therapeutics news, CFO Adam Scott Levy sold 10,757 shares of the firm’s stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $13.14, for a total value of $141,346.98. Following the transaction, the chief financial officer now owns 247,611 shares in the company, valued at approximately $3,253,608.54. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Brian Taylor Slingsby sold 550,000 shares of Mineralys Therapeutics stock in a transaction on Wednesday, July 24th. The stock was sold at an average price of $13.05, for a total transaction of $7,177,500.00. Following the sale, the director now directly owns 8,644,579 shares in the company, valued at approximately $112,811,755.95. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 577,028 shares of company stock worth $7,536,774. Company insiders own 33.24% of the company’s stock.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.